Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare , Dhahran, Saudi Arabia.
Department of Medicine, Indiana University School of Medicine , Indianapolis, IN, USA.
Hum Vaccin Immunother. 2020 Dec 1;16(12):2973-2979. doi: 10.1080/21645515.2020.1793712. Epub 2020 Sep 3.
The emergence of the COVID-19 pandemic has resulted in a very large number of infections and high number of mortality. There is no specific therapeutic options that are approved for clinical use. Administration of convalescent plasma as a possible therapy was used in the case of viral pneumonia including SARS and influenza. There have been multiple studies of COVID-19 patients utilizing convalescent plasma. These studies employed different dosage levels and different regiments, were observational and lacked control arms, and had variable outcomes. Two of these studies used plasma with anti-SARS-CoV-2 titers of >1:640 to >1:1000. A recent randomized controlled clinical trial showed no benefit of convalescent plasma in patients with severe diseases. However, the study was terminated early and thus further clinical trials are needed to show efficacy in patients with COVID-19 infection.
新冠疫情大流行导致了大量感染和高死亡率。目前尚无经批准用于临床的特定治疗方法。在病毒性肺炎（包括 SARS 和流感）的情况下，使用恢复期血浆作为一种可能的治疗方法。已经有多项针对 COVID-19 患者使用恢复期血浆的研究。这些研究采用了不同的剂量水平和方案，为观察性研究且缺乏对照组，结果也各不相同。其中两项研究使用了 SARS-CoV-2 滴度大于 1:640 至大于 1:1000 的血浆。最近的一项随机对照临床试验显示，重症患者使用恢复期血浆没有益处。然而，该研究提前终止，因此需要进一步的临床试验来证明 COVID-19 感染患者的疗效。
